Cancer vaccines: should we be targeting patients with less aggressive disease?. (June 2012)

• Record Type: Journal Article
• Authors: Hale, Diane F; Clifton, G Travis; Sears, Alan K; Vreeland, Timothy J; Shumway, Nathan; Peoples, George E; Mittendorf, Elizabeth A
• Is Part Of: Expert review of vaccines. Volume 11:Number 6(2012)
• Page Start: 721
• Page End: 731
• Publication Date: 2012-06
• Subjects: biologic factors -- cancer vaccines -- clinical trials -- early-stage disease -- immunotherapy -- metastatic disease; Vaccines -- Periodicals; Vaccination -- Periodicals; 615.37205
• DOI: 10.1586/erv.12.39
• Languages: English
• ISSNs: 1476-0584

Abstract

There is enthusiasm for using vaccines to stimulate the immune system to treat cancer. In this article, the authors review the evolution of vaccines evaluated in clinical trials, starting with Phase III trials in metastatic disease and progressing to trials in the adjuvant setting. Data from these trials suggest that cancer vaccines may be more effective in patients with lower volume disease, and data from the E75 peptide vaccine trials suggest that vaccines may be most effective in less aggressive disease.